The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(7 sites)
Belgium
Laboratory for Muscle Diseases and Neuropathies, Leuven Denmark
Aarhus University Hospital, Aarhus Germany
Ludug-Maximilians University, München Italy
Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome Spain
University Hospital of Madrid, Madrid United Kingdom
Saint George's University Hospitals NHS Foundation Trust, London University College Hospital, London Age range
16 Years and older
Last updated February 2026